Biosimilars in rheumatology: understanding the rigor of their development
about
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.CT-P13 in the treatment of rheumatoid arthritis.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
P2860
Biosimilars in rheumatology: understanding the rigor of their development
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Biosimilars in rheumatology: understanding the rigor of their development
@ast
Biosimilars in rheumatology: understanding the rigor of their development
@en
Biosimilars in rheumatology: understanding the rigor of their development
@nl
type
label
Biosimilars in rheumatology: understanding the rigor of their development
@ast
Biosimilars in rheumatology: understanding the rigor of their development
@en
Biosimilars in rheumatology: understanding the rigor of their development
@nl
prefLabel
Biosimilars in rheumatology: understanding the rigor of their development
@ast
Biosimilars in rheumatology: understanding the rigor of their development
@en
Biosimilars in rheumatology: understanding the rigor of their development
@nl
P2860
P356
P1433
P1476
Biosimilars in rheumatology: understanding the rigor of their development
@en
P2093
Kamali Chance
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEW206
P50
P577
2016-05-30T00:00:00Z